SpecGx LLC secured FDA approval for filing ANDA040405, gaining market access for generic HYDROCODONE BITARTRATE AND ACETAMINOPHEN. The entry of this generic alternative is expected to intensify market competition and erode pricing power for branded formulations in the opioid analgesic sector.